Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

David Cameron(NHS Lothian), Julia Brown(University of Leeds), Rebecca Dent(Sunnybrook Health Science Centre), Christian Jackisch(Sana Klinikum Offenbach), John R. Mackey, Xavier Pivot(Centre Hospitalier Universitaire de Besançon), Guenther G. Steger(Medical University of Vienna), Thomas Suter(University Hospital of Bern), Masakazu Toi(Kyoto University), Mahesh Parmar(Medical Research Council), R. Laeufle(Roche (Switzerland)), Young‐Hyuck Im(Samsung Medical Center), Gilles Romieu(Institut de Recherche en Cancérologie de Montpellier), Vernon Harvey(Auckland City Hospital), Oleg Lipatov(Republican Oncological Clinical Dispensary), Tadeusz Pieńkowski(Postgraduate School of Molecular Medicine), Paul Cottu(Institut Curie), Arlene Chan(Curtin University), Seock‐Ah Im(Seoul National University), Peter Hall(University of Leeds), Lida Bubuteishvili‐Pacaud(Roche (Switzerland)), Volkmar Henschel(Roche (Switzerland)), Regula Deurloo(Roche (Switzerland)), Céline Pallaud(Roche (Switzerland)), Richard H. Bell
The Lancet Oncology
August 6, 2013
Cited by 435

Abstract


Related Papers

No related papers found

Powered by citation graph analysis